High selectivity for MC4R significantly reduces potential for skin pigmentation MC4R is a well-validated target for treating obesity Clinical studies with highly selective MC4R agonists targeted to commence in calendar year 2025 CRANBURY, N.J., Oct. 23, 2024 /PRNewswire/ -- Palatin...
Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium
Seaking AlphaSeeking Alpha / Seaking Alpha 4 hours ago 1 Views
Comments